Strength Amidst Struggles: Emerging Adults with ADHD
Summary
This study intends to investigate resilience and stressors such as stigma, anti-mattering, loneliness, and stress. The purpose is to understand how young adults with ADHD and without ADHD are both thriving and struggling. The study will ask participants to fill out questionnaires online. Participants will be entered into a draw for one of several $25 giftcards as a thanks for participating. The draw will take place in a few months after recruitment is finished.
Eligibility
Eligible ages: 18 to 25
Accepts healthy participants: Yes
Inclusion criteria:
We are looking for both people with AND without ADHD.
Young adults who are:
1) Between 18 to 25 years of age.
2) Communicate in English (read and oral communication).
For ADHD Group: 3a) Either have a formal ADHD diagnosis from a medical or mental health professional.
For Without ADHD Group: 3b) Have no diagnosis of ADHD.
Exclusion criteria:
1) Must have no previous diagnosis of psychosis, epilepsy, or major gross neurological, sensory, or motor impairments.
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
adhdkids@ucalgary.ca
Principal investigator:
Emma Climie
Clinical trial:
No
REB-ID:
REB25-1485